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Abstract
Background: Although current chemotherapy regimens have remarkably improved the cure rate of pediatric acute
promyelocytic leukemia (APL) over the past decade, more than 20% of patients still die of the disease, and the 5-
year cumulative incidence of relapse is 17%. The precise gene pathways that exert critical control over the
determination of cell lineage fate during the development of pediatric APL remain unclear.
Methods: In this study, we analyzed miR-125b expression in 169 pediatric acute myelogenous leukemia (AML)
samples including 76 APL samples before therapy and 38 APL samples after therapy. The effects of enforced
expression of miR-125b were evaluated in leukemic cell and drug-resistant cell lines.
Results: miR-125b is highly expressed in pediatric APL compared with other subtypes of AML and is correlated
with treatment response, as well as relapse of pediatric APL. Our results further demonstrated that miR-125b could
promote leukemic cell proliferation and inhibit cell apoptosis by regulating the expression of tumor suppressor
BCL2-antagonist/killer 1 (Bak1). Remarkably, miR-125b was also found to be up-regulated in leukemic drug-resistant
cells, and transfection of a miR-125b duplex into AML cells can increase their resistance to therapeutic drugs,
Conclusions: These findings strongly indicate that miR-125b plays an important role in the development of
pediatric APL at least partially mediated by repressing BAK1 protein expression and could be a potential
therapeutic target for treating pediatric APL failure.
Keywords: microRNA, pediatric acute promyelocytic leukemia (APL), treatment response, drug resistance
Background
Pediatric acute promyelocytic leukemia (APL), which
represents approximately 10% of pediatric AML cases, is
a subgroup of acute myelogenous leukemia (AML) char-
acterized by promyelocytic cell morphology (referred to
as M3 in the French-American-British classification)
[1-3]. APL is characterized by a specific t(15;17) translo-
cation that encodes a fusion of the promyelocytic leuke-
mia (PML) and retinoic acid receptor-a (RARA)
proteins [1-5]. Although the outcomes for children and
adults with APL have dramatically improved since the
successful introduction of all-trans retinoic acid (ATRA)
in combination with anthracycline-based chemotherapy,
more than 20% of patients presenting with APL will die
of the disease, and the 5-year cumulative incidence of
relapse is 17% overall and more than 20% in children
[6-8]. The combination of ATRA and chemotherapy as
initial therapy has become an attractive strategy for all
APL patients; unfortunately, approximately 10% of APL
patients develop “retinoic acid syndrome (RAS)” [6,9,10].
Furthermore, the precise genes and pathways that exert
critical control over the lineage fate during APL devel-
opment remain unclear.
MicroRNAs (miRNAs), a novel class of small noncod-
ing RNAs ranging from 19 to 25 nucleotides in size, reg-
ulate specific target genes through translational
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ing many cellular functions, including cell proliferation,
differentiation, and apoptosis [11-13]. Recent studies
have shown that deregulated expression of specific miR-
NAs that modulate expression of oncogenes and tumor
suppressors is associated with the development of malig-
nancies and that specific miRNA expression signatures
can be used to effectively classify human tumors [14].
MiRNA expression signatures associated with specific
cytogenetic changes and clinical outcomes of adult CLL,
AML, and Hodgkin’s lymphoma have been reported
[15-20]. Recent data suggest that miRNA inactivation by
epigenetic mechanisms plays an important role in mye-
lopoiesis and that modulating specific miRNA levels
with drugs can lead to the downregulation of target
oncogenes and restoration of cell differentiation [21].
Dysregulated miRNA expression in APL cells following
retinoic acid (RA) induction was also reported [22-25].
These studies, however, mainly focused on APL cell
lines and included very few clinical APL samples. The
role of miRNAs in the clinical progression of APL, espe-
cially in pediatric APL, remains to be explained.
Our previous study found that miR-125b was up-regu-
lated in pediatric primary AML using genome-wide
miRNA expression profiles in 36 diagnostic acute leuke-
mia bone marrow samples [26]. To further understand
t h er o l eo fmiR-125b in pediatric AML, we analyzed
miR-125b expression in 169 pediatric AML patients for
whom clinical data were available. Interestingly, we
found that miR-125b was reduced to normal levels in
complete remission (CR) APL patients. Importantly, we
found that miR-125b could promote proliferation and
inhibit apoptosis of APL cells by targeting BCL2-antago-
nist/killer 1 (Bak1). The results imply that miR-125b
functions as an oncogene in pediatric APL and that it
has potential roles as a malignancy biomarker and a pre-
dictive marker of response to chemotherapy. In addition,
we showed that transfection of the cells with miR-125b
could increase cell resistance to chemotherapeutic drugs.
Methods
Patients, sample collection, and therapeutic methods
A total of 182 pediatric samples including 131 AML sam-
ples before therapy (including 76 PML-RARa-positive
APL samples), 38 APL samples (PML-RARa-positive)
after therapy and 13 normal samples from the First and
Second Affiliated Hospital of Sun Yat-sen University and
Beijing Children’s Hospital were enrolled in this study.
Patients’ characteristics are available for all patients (see
Table 1). Bone marrow was collected from patients by
bone marrow puncture at diagnosis or at follow-up after
therapy. The treatment protocol for AML patients is listed
in Additional file 1. Table S1. Written informed consent
for the biological studies was obtained from the parent/
guardians. The study was approved by the Ethics Commit-
tee of the affiliated hospitals of Sun Yat-sen University.
Cell lines and cell cultures
Human leukemia cell line NB4, HL60, K562 and their
drug resistant cell lines were maintained in RPMI 1640
Table 1 Pediatric AML patients’ characteristics
AML Primary (N = 131) Characteristics Median (range) No. (%)
Age at diagnosis, y 7.8 (0-14)
Sex
Male 79 (60.3)
Female 52 (39.7)
WBC count, ×10
9/L 18.2 (1.1-292)
Less than 10 76 (58)
10-50 34 (26)
50 or higher 21 (16)
FAB
M1 9 (6.9)
M2 27 (20.6)
M3 76 (58)
M4 5 (3.8)
M5 11 (8.4)
M6 3 (2.3)
M3 after therapy (N = 38) #CR 33 (86.8)
&Relapse 5 (13.2)
AML: acute myelogenous leukemia; WBC: white blood cell; FAB: French-American-British classification; CR: complete remission.
#: CR samples are from 33 patients of 76 M3 primary patients with three years clinical follow-up;
&: with three years clinical follow-up.
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Page 2 of 13medium containing 10% fetal bovine serum (Gibco BRL).
Drug resistant cell lines included NB4-R1 (subclones of
NB4 with ATRA resistance established by ATRA inducing
progressively), NB4-R2 (subclones of NB4 with ATRA
resistance established by mutating the E domain of PML/
RARA), HL60/DOX (subclone of HL60 with doxorubicin-
resistance established by drug inducing progressively) and
K562/DOX (subclone of K562 with doxorubicin-resistance
established by drug inducing progressively). 293 T cell line
was maintained in DMEM medium containing 10% fetal
bovine serum (Gibco BRL).
Mouse model
Five-week-old BALB/c (nu/nu) mice were maintained
under a specific pathogen-free condition in the Labora-
tory Animal Center, Sun Yat-sen University. All experi-
ments were performed in accordance with our
Institutional Animal Guidelines. The xenografted tumors
were established by a single subcutaneous injection at the
flank of ALB/c (nu/nu) mice with 2 × 10
6 HL60 cells
(infected with lentivirus vectors that expressed miR-125b
or miRNA negative control) in 0.1 ml RPMI-1640 med-
ium. Each group consisted of at least 3 mice. The tumors
were harvested, snap-frozen and stored at -80°C.
RNA extraction and quantitative real-time polymerase
chain reaction
Total RNA was isolated with Trizol (Invitrogen, Carls-
bad, CA) according to the manufacturer’si n s t r u c t i o n s .
The following two quality criteria were used to assess
total RNA quality. The first is purity. Both ratios, OD
A260/A280 and OD A260/A230 were in the 1.8-2.1
region. The second is integrity. Total RNA quality has
been assessed by denaturing gel electrophoresis electro-
phoresis and the ratio of 28S and 18S rRNA bands was
approximately 2:1. Quantitative real-time RT-PCR (qRT-
PCR) was performed as described [27] and employed a
Hairpin-it™ miRNAs Real-Time PCR Quantization Kit
containing stem-loop like RT primer, miRNA specific
PCR primer and Molecular Beacon probe for miR-125b
or the U6 RNA internal control (GenePharma, Shanghai,
China). The expression of miR-125b relative to that in
healthy samples was calculated using the 2-ΔΔCT
method, and the expression of miR-125b relative to
internal control U6 RNA in mouse was calculated using
the 2-ΔCT method [28]. The efficiencies of PCR amplifi-
cation per PCR-cycle (by a dilution curve) of both miR-
125b and U6 from each patient are higher than 95%
(Additional file 2. Figure S1).
Statistical analysis
Fisher’s exact test, paired t-test, and chi-square tests
were used to compare baseline characteristics and aver-
age miRNA expression between different groups. All
reported P values were two-sided and were obtained
using SPSS software. P < 0.05 is considered significant.
Target genes prediction
Target genes prediction was performed to meet the
following two criteria. First, miRNA targets were ana-
lyzed using three algorithms, including TARGETSCAN
http://www.targetscan.org, PICTAR http://pictar.mdc-
berlin.de and miRBase http://microrna.sanger.ac.uk/
sequences/index.shtml. Second, in order to reduce the
number of false positives, only putative target genes
predicted by at least two of the programs were
accepted.
Western blotting
Cells were homogenized in a lysis buffer (25 mM Tris-
HCl (pH 7.4), 0.5 mM EDTA, 0.5 mM EGTA, 1 mM
PMSF, 25 μg/ml leupeptin, 1 mM DTT, 0.5% Triton X-
100) and centrifuged. Samples of supernatant, each con-
taining 10 μg of total protein, were electrophoresed in a
5-15% gradient gel. Western blotting was performed as
following. In brief, the proteins were transferred to poly-
vinylidene difluoride (PVDF) membranes. The mem-
branes were blocked in 4% non-fat dry milk in Tris-
buffered saline containing 0.1% Tween 20 (TBST) for 1
hr at room temperature and then probed overnight with
rabbit polyclonal anti-Bak1 antibody (Sigma) in the
same buffer. After three washes with TBST, the mem-
branes were incubated for 1 hr with goat anti-rabbit IgG
antibody (Sigma) conjugated to horseradish peroxidase
(HRP). After washing with TBST, the membranes were
exposed to a chemiluminescent reagent (ECL Plus,
Amersham) for 1 min and then to Kodak X-ray film.
Anti-b-actin antibody and anti-tublin antibody (Cell sig-
naling technology) has been used to detect beta-actin
and tublin.
MiR-125b expression vector construct
Full-length double-stranded human pre-miR-125b,
together with 305 bp of flanking sequence was amplified
from human genomic DNA using PCR (primer informa-
tion is available in Additional file 3. Table S2) and cloned
into the pcDNA™6.2-GW/EmGFP-miR control vector
(Invitrogen) to generate the miR-125b expression con-
struct pcDNA-miR-125b. The PCR product was also
cloned into pIRES2-EGFP (Invitrogen, Carlsbad, CA,
USA) and the fragment containing CMV promoter and
miR-125b precursor was then cloned into pINCO retro-
viral vector (Genechem, Shanghai, China) to generate lv-
miR-125b. Insertions were verified by DNA sequencing.
pGL3-BAK1 reporter construct and mutagenesis
The 252 bp 3’-untranslated terminal region (UTR) seg-
ment of Bak1 was amplified by PCR from human
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tor (Promega) using the XbaI site immediately down-
stream from the stop codon of luciferase for miR-125b
functional analysis. Similarly, recombinant pGL3 repor-
ter vectors for other selected possible targets were con-
s t r u c t e d .T h eB a k 1m u t a n t ,p G L 3 - B A K 1 - M ,w h i c hh a d
8 bp deleted from the site of perfect complementarity to
miR-125b, was generated using PCR deletion Wild-type
and mutant insertions were confirmed by DNA sequen-
cing. Primer information is available in Additional file 3.
Table S2.
Luciferase assay
0.2 μg of pcDNA-miR-125b or pcDNA-control was
cotransfected to 293 T cells with 0.1 μgo fp G L 3 - c o n t r o l
or recombinant pGL3 reporter vector and 0.1 μgo ft h e
control vector pRL-TK containing Renilla luciferase and
TK promoter (Promega) using lipofectamine 2000 (Invi-
trogen). For NB4 cells, 5 μg of pcDNA-miR-125b or
pcDNA-control, 5 μg of pGL3-control or pGL3-BAK1 or
pGL3-BAK1-M Firefly luciferase report vector and 2.5 μg
of the control vector pRL-TK were cotransfected using
electroporation. 293 T cells or NB4 cells were grown in
24-well plates (1 × 10
5 cells/well) in 10% FBS in DMEM
or RPMI-1640 supplemented with sodium pyruvate at
37°C in a humidified atmosphere of 5% CO2. Firefly and
Renilla luciferase activities were measured consecutively
using dual-luciferase assays (Promega) 24 hrs after trans-
fection, according to the manufacturers’ instructions.
Cell proliferation and apoptosis assay
NB4 cells, HL60 cells, NB4-R1 cells, NB4-R2 cells and
HL60/DOX cells (1 × 10
4 per well) were plated in 96-
well plates in RPMI medium 1640 and 10% FBS that
was supplemented with sodium pyruvate at 37°C in a
humidified atmosphere of 5% CO2. Cells were trans-
fected with 100 nM miR-125b duplex (Ambion),
scrambled duplex (negative control, Ambion), or 200
nM miR-125b antisense (Ambion) using lipofectamine
2000 (Invitrogen). After culturing for 1, 2 or 3 days, the
MTT assay (Promega) or CCK-8 assay (Dojindo Mole-
cular Technologies) was carried out to analyze cell pro-
liferation. For apoptosis, forty-eight hours following the
transfection, cells were labeled with Annexin V/PI (Mul-
tiSciences Biotech) and analyzed by flow cytometry.
Cell cytotoxicity assay
HL60 or HL60/DOX cells were seeded in 24-well plates
at a density of 3 × 10
5 cells per well and transfected
with 100 pmol scrambled duplex, miR-125b duplex or
miR-125b antisense, or scrambled duplex (Ambion) in
three independent replicates, using Nenon transfection
equipment (Invitrogen) according to the manufacturer’s
protocol with program settings of 1400 V, 10 ms width,
and 3 pulses. Forty-eight hours after transfection, cells
were reseeded in 96-well plates at a density of 1.5 × 10
4
per well in the presence of miR-125b and treated with
doxorubicin at a range of concentrations (5 to 25 μg/
ml) in medium for 72 hrs. Cell survival was analyzed
using the Cell Titer 96 Aqueous One Solution Cell Pro-
liferation Assay (Promega).
Results
miR-125b is highly expressed in pediatric APL
Using genome-wide miRNA expression profiles in 36
diagnostic acute leukemia bone marrow samples, we
previously identified 17 up-regulated and 18 down-regu-
lated miRNAs that were significantly deregulated in
pediatric primary AML compared with healthy samples
[26]. Remarkably, miR-125b was significantly up-regu-
lated in pediatric APL patients compared with other
AML subtypes (Figure 1A). This result was further con-
firmed by northern blot (Figure 1B). This finding raised
the possibility that miR-125b might play an important
role in the development of pediatric APL.
To clarify the differential expression pattern of miR-
125b, we performed large-scale qRT-PCR assays on
bone marrow samples from 131 pediatric primary AML
samples, including 76 APL patients with PML-RARa-
positive APL and 55 patients with other subtypes (M1,
M 2 ,M 4 ,M 5 ,M 6 ) .A ss h o w ni nF i g u r e1 C ,miR-125b
showed exceptionally high expression in APL (average
of 760-fold higher than the normal population),
although miR-125b expression in other subtypes was
also higher than normal. However, the expression of
miR-125b was not significantly different between
younger (less than 10 years of age) and older (between
10 and 14 years of age) pediatric patients (Figure 2A).
Our results suggested that miR-125b might be involved
in APL pathogenesis and that it might be used as a bio-
marker for malignancy in pediatric APL.
Induction therapy suppresses miR-125b expression in
pediatric APL
All pediatric APL (M3 subtype) patients received a sub-
stantially distinct therapy utilizing the modified
PETHEMA protocol (Additional file 1. Table S1) after
diagnosis. We then collected 33 matched-pair APL sam-
ples at diagnosis and complete remission (CR) with
PML-RARa-positive and with three years of clinical fol-
low-up. We also collected 5 relapsed patients for com-
parison. To establish the relevance of miR-125b
expression before and after therapy treatment, we inves-
tigated miR-125b expression in pairs of samples with
diagnosis-CR or diagnosis-relapse. The results showed
that in all CR patients, miR-125b expression decreased
sharply after therapy to the same levels as in the normal
c o n t r o l s( F i g u r e2 B ) ,w h i c hm a yb ed u et ol a r g e l y
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expression level in the relapse patients was higher than
normal controls, although induction therapy suppressed
miR-125b expression in these patients to some degree
(Figure 2C). The significantly different expression of
miR-125b between pediatric primary, CR and relapse
patients suggested that miR-125b could be a biomarker
for clinical outcome. This possibility will be further stu-
died using a larger number of patients. This finding
raised the possibility that miR-125b, which is involved in
the timing of tissue development and cell differentiation
[29], might function as an oncogene in pediatric APL.
miR-125b represses endogenous Bak1 protein in myeloid
cell lines and pediatric APL samples and is associated
with disease development and treatment outcomes
Elucidating the targets of miRNAs is still a major part of
the miRNA functional investigation. We selected 15
potential targets that contain the conserved miRNA
response elements (MREs) of miR-125b in their 3’ UTR
and had been reported to be related to leukemogenesis
for further experimental investigation. Among them, we
confirmed that four putative targets (BAK1, MAP3K10,
MCL1, and TRIAP1) were repressed by miR-125b when
transfected to 293T cells, with a repression rate of more
than 25%, as measured by a luciferase assay (Additional
file 4. Figure S2A). Remarkably, we found that the
tumor suppressor Bak1 had the most reduced activity,
which suggested that Bak1 was likely to be an important
target regulated by miR-125b in leukemia. To further
test our hypothesis, we constructed a recombinant
pGL3-BAK1-M with a mutant miR-125b binding site
(Figure 3A). pGL3-BAK1 and pGL3-BAK1-M were then
cotransfected into NB4 cells either with or without
pcDNA-miR-125b using the electroporation method. As
shown in Figure 3B, transfection of miR-125b reduced
Figure 1 Differential expression of miR-125b in pediatric AML patients. (A) Differential expression of miR-125b in normal samples and
different subtypes of pediatric AML determined by miRNA microarray analysis (the same part of different microarray chips is shown). Bright
green dots indicate highly expressed miRNAs. (B) Expression of miR-125b in the normal pool (N); different subtype pools of pediatric AML and
M3 complete remission pool (M3 CR) were validated by northern blot. (C) Expression levels of miR-125b in subtypes of 131 pediatric AML were
analyzed with qRT-PCR. Data are presented as the fold change of miR-125b expression in patient samples with respect to expression in bone
marrow mononuclear cells (MNC) from 13 healthy donors. The average miR-125b expression of each subtype was statistically compared with the
average normal value. *p < 0.05; **p < 0.01.
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by about 40%. However, in NB4 cells transfected with
either wild-type or mutant reporter in the absence of
pcDNA-miR-125b, there was almost no change in
luciferase activity. This finding demonstrates that Bak1
is a target of miR-125b in leukemic cells and that the
putative miR-125b binding site is critical for miR-125b
regulation of Bak1 expression.
To further investigate whether overexpression of miR-
125b can promote APL myeloid cell progression by tar-
geting tumor suppressor Bak1, we transfected two APL
cell lines (NB4 and HL60) with 100 nM miR-125b
duplex using the electroporation method (Additional file
4. Figure S2B). Bak1 expression was strongly reduced
compared with that transfected with scrambled duplex
in both myeloid cell lines NB4 (Figure 3C, left panel)
a n dH L 6 0( F i g u r e3 C ,r i g h tp a n e l ) .T ou n c o v e rt h e
effects of suppression in vivo, HL60 cells were infected
with lentivirus vectors that expressed miR-125b (lv-miR-
125b) or miRNA negative control (lv-NC), and then
transplanted into nude mice with SC injection. Both
groups of mice transplanted with lv-miR-125b-HL60
cells and lv-NC-HL60 cells developed solid tumors three
weeks later. The overexpression of miR-125b was exam-
ined using qRT-PCR (Figure 3D, upper). The western
blot analysis showed the Bak1 protein was repressed in
the lv-miR-125b-HL60 tumors compared with the lv-
NC-HL60 tumors transplanted with miRNA negative
control (Figure 3D, lower).
Next, to examine the possibility that Bak1 was also regu-
lated by miR-125b in clinical samples, we measured the
expression levels of these two molecules in 47 pediatric
APL clinical samples (only 47 samples have enough pro-
teins to be used for western blot ananlysis) and five nor-
mal donors. We found that the levels of Bak1 and miR-
125b were inversely correlated in 70.2% (33/47) of the
pediatric APL samples (Figure 3E). For comparison, Figure
3F illustrates typical Bak1 protein expression in the 33
samples with the highest (APLH) and lowest (APLL) levels
of expressed miR-125b. The levels of miR-125b expression
for APLH and APLL were 80,071-fold and 10.24-fold
higher than the normal average, respectively, while the
levels of Bak1 expression were 50-fold lower in APLH and
2-fold lower in APLL. These results strongly suggest that
Bak1 is a target of miR-125b in pediatric APL.
Because induction therapy suppressed miR-125b
expression in pediatric APL patients, we would expect
that, as a target of miR-125b, Bak1 levels would also be
affected by therapeutics. We therefore analyzed the
levels of Bak1 and miR-125b in samples from follow-up
patients and compared the profiles with the profiles
obtained from the same patients before therapy. In addi-
tion, three normal marrows were used as controls. Bak1
expression was increased in about 60% of CR patients
(19/33) receiving therapeutics (Figure 3G). Thus, a con-
cordant negative correlation existed between miR-125b
levels and Bak1 levels with respect to disease develop-
ment and treatment outcome.
Figure 2 Expression of miR-125b varied in different therapeutic
response groups of pediatric APL. The qRT-PCR assay was repeated
three times, and similar results were obtained. Representative results
are shown as means ± standard deviation (M ± SD). Data presented
are the fold changes of expression with respect to the bone marrow
MNC from five healthy donors. (A) Expression level of miR-125b in
different age groups of pediatric APL patients. (B) The expression levels
of miR-125b in 33 pediatric APL patients before and after therapy are
presented as fold changes of expression with respect to expression in
bone marrow mononuclear cells (MNC) from healthy donors. MiR-125b
levels for the same patient before and after therapy were paired. Data
were sorted from lowest to highest levels of miR-125b in non-treated
patients. (C) Expression level of miR-125b in pediatric APL patients
before and after therapy. *p < 0.05, **p < 0.01.
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Page 6 of 13Figure 3 Exogenous miR-125b deregulates Bak1 protein. (A) An outline of luciferase reporter assay for validating the interaction of miR-125b
with the 3’ UTR of BAK1 is shown. Red text indicates the ‘’seed’’ regions. In mutant reporter constructs, the MRE was deleted. (B) Repression of
luciferase activity due to the interaction between miR-125b and the predicted MREs in the luciferase-Bak1-3’ UTR constructs. The values represent
the average ± SD (n = 3). *p < 0.05. (C) Western blot analysis of BAK1 expression in NB4 cells (left panel) or HL60 cells (right panel) after
transfection with 100 nM miR-125b duplex or scrambled duplex. (D) The effects of suppression of miR-125b on Bak1 in mouse model. Upper: the
overexpression of miR-125b was examined using qRT-PCR; lower: western blot analysis showed the Bak1 protein was repressed by miR-125b. lv-
miR-125b: lentivirus vectors that expressed miR-125b; lv-NC: lentivirus vectors that expressed miR-NC, miRNA negative control. (E) Bak1 protein
expression was inversely correlated with miR-125b levels in 33 of 47 pediatric APL patient samples. Red triangle: miR-125b expression (fold
change vs. normal average); light blue diamond: Bak1 protein expression (fold change vs. normal average). Both miR-125b and Bak1 average
expression levels of healthy donors were set at 1. (F) Western blotting images showing typical high and low Bak1 protein expression levels. The
Bak1 protein level was quantified from western blot bands normalized to the b-actin level. The average expressions of Bak1 and miR-125b,
presented as fold change compared with healthy samples, are listed in the table. (G) Bak1 protein expression in three normal donors using
western blot (left), selected typical Bak1 protein expression in normal donor and pediatric patients with different ATRA responses was analyzed
by western blot (right). N, normal donor; P, samples collected in primary diagnosis without treatment; CR, complete remission after therapy.
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and inhibits apoptosis of leukemic cells
Bak1 is a pro-death protein and can promote pro-
grammed cell death [30]. Overexpression of miR-125b,
which inhibits Bak1 expression, may therefore result in
reduced apoptosis and enhanced proliferation of leuke-
mic cells and further induce oncogenesis. Thus, we mea-
sured cell proliferation and viability of transfected NB4
cells using an MTT assay and CCK-8 assay. As expected,
proliferation of NB4 cells was stimulated by the trans-
fected miR-125b duplex (Figure 4A) or lv-miR-125b
(Additional file 5. Figure S3), and the effect was time-
dependent. In addition, transfection of HL60 cells with
100 nM miR-125b promoted cell proliferation (Figure
4B). These results showed that miR-125b may function as
an oncogene and may contribute to APL progression.
Figure 4 miR-125b promotes cell proliferation and inhibits apoptosis in leukemic cell lines NB4 and HL60. (A) Time-dependent effects of
miR-125b on NB4 cell proliferation were confirmed using an MTT assay. (B) Time-dependent effects of miR-125b on HL60 cell proliferation were
confirmed using an MTT assay. At least three independent experiments were performed and similar results were obtained. Data are represented
as means ± SD from 3 independent experiments. P < 0.05, compared with mock, scrambled duplex and miR-195 at 48, 72 and 96 hrs. (C)
Apoptosis in a leukemic cell line transfected with miR-125b duplex, as detected by flow cytometry. Upper panel: The NB4 cells were transfected
with 100 nM scrambled duplex, miR-195 or miR-125b duplex, respectively. Lower panel: The NB4 cells were transfected with 100 nM antisense
control, miR-195 or miR-125b antisense, respectively. Forty-four hours following transfection, camptothecin was added to induce cells for four
hours and then cells were labeled with Annexin V/PI and analyzed by flow cytometry. Three independent experiments were performed and
similar results were obtained.
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with miR-125b duplex (mimics) and miR-125b inhibitor
(anti-miR-125b) to assess the possible role of miR-125b in
apoptosis in leukemic cells. However, in cancer cells, p53
and Bak1 protein are mainly localized in the cytoplasm, so
the endogenous activity of Bak1 is usually insufficient to
modulate apoptosis [31]. Additionally, a previous study
showed that ectopic expression of miR-125b in cells only
suppresses apoptosis when the mitochondrial pathway is
fully activated by exposure to the drug [32]. We then trea-
ted the cells with 7-ethyl-10-hydrol-camptothecin and per-
formed flow cytometry assays after 48 hrs of transfection.
The results showed that ectopic expression of miR-125b
significantly suppressed 7-ethyl-10-hydrol-camptothecin-
induced apoptosis of NB4 cells (Annexin V-FITC positive)
compared with control and miR-195 duplex (Figure 4C,
upper panel).
The ability of transfection with miR-125b antisense to
control apoptosis was also examined. Interestingly, after
being transfected with 100 nM miR-125b (antisense),
the percentage of 7-ethyl-10-hydrol-camptothecin-
induced apoptotic NB4 cells (ANNEXIN V-FITC posi-
tive) at 48 hrs increased compared with control and
miR-195 duplex (Figure 4C, lower panel). Similar results
were obtained in HL60 cells (Additional file 6. Figure
S4A). These results demonstrate that transfection of
miR-125b antisense can remarkably increase cell apopto-
sis in leukemia cells. Furthermore, we inferred that miR-
125b directly regulates Bak1 expression, thereby modu-
lating the susceptibility of leukemic cells to apoptosis.
To prove the physiological relevance of Bak1, RNAi
against Bak1 was performed to analyze its role in myeloid
cell apoptosis. The transfection of NB4 cells with differ-
ent pieces of siRNAs against the Bak1 mRNA resulted in
greatly decreased levels of the endogenous protein Bak1,
especially for the pieces si-Bak1-1, si-Bak1-2 and si-Bak1-
3 (Figure 5A). To test if down-regulation of Bak1 was
able to inhibit myeloid cell apoptosis, we detected cell
apoptosis 48 hrs after transfection of NB4 cells with si-
Bak1-3 and a mixture of the three strands of siRNA. The
number of apoptotic leukemic cells was obviously
reduced by the subsequent downregulation of Bak1 (Fig-
u r e5 B - D ) .A l t o g e t h e r ,t h e s ed a t ai n d i c a t et h a tt h ea r t i f i -
cial increase of miR-125b or reduction of Bak1 levels was
able to inhibit myeloid leukemic cell apoptosis.
Up-regulation of miR-125b levels was found in resistant
cells and reduction of the expression levels increased
their sensitivity to therapeutic drugs
We noted above that the expression of miR-125b in all
CR patients normalized after therapy, while it remained
much higher in relapse patients (Figure 2C). We also
found that miR-125b expression was slightly up-regu-
lated in four drug-resistant cell lines, including HL60/
DOX, K562/DOX (subclone of K562 with doxorubicin-
resistance) and NB4-R1, as well as NB4-R2 (subclones
of NB4 with ATRA resistance), when compared with
their drug-sensitive parental cells (Figure 5E). These
findings imply that miR-125b contributes to the drug-
resistant nature of leukemic cells and that up-regulation
of miR-125b levels in cells may increase their resistance
to therapeutic drugs.
To address this issue, we transfected drug-resistant
HL60/DOX cells and NB4-R1 with miR-125b duplex.
Transfection of HL60/DOX cells with miR-125b duplex
increased their resistance to DOX treatment. The IC50
of HL60/DOX cells transfected with miR-125b duplex
was higher (p < 0.05) compared with the IC50 for
HL60/DOX cells transfected with the miRNA duplex
control and miR-195 duplex (Figure 5F). We also repro-
duced the same experiment in NB4-R1, and the results
are shown in Additional file 6. Figure S4B. Taken
together, the above results indicate a link between miR-
125b dysregulation and drug resistance. However, the
precise pathway and mechanism of action of miR-125b
in the acquisition of drug resistance remains elusive.
Discussion
In our previous investigation, we analyzed genome-wide
miRNA expression profiles in pediatric AML and identi-
fied miRNA patterns specific to this disease. We also
found that unique miRNA expression profiles were pre-
sent in different subtypes of AML [26]. These results
imply that particular miRNAs might have specific roles
in carcinogenesis or in the development of certain sub-
types of leukemia. We noted that the expression of
some miRNAs, including miR-125, was strikingly higher
in pediatric APL than other subtypes of AML. This phe-
nomenon led us to consider whether these miRNAs are
oncogenic, whether they cause specific subtypes of
pediatric leukemia or simply accompany them, or, alter-
natively, whether they represent a tumor suppressor
feedback mechanism that is superseded by malignancy.
Elucidating these questions should enhance our under-
standing of the malignant progression of pediatric APL.
Therefore, to address these questions, we focused on
the role of highly up-regulated miR-125b in pediatric
APL.
The expression of miR-125b has been investigated in
many human cancers. It is down-regulated in human
breast cancer, thyroid anaplastic carcinomas, ovarian
cancer, squamous cell carcinoma of the tongue, and
hepatocellular carcinoma, suggesting that it functions as
a tumor suppressor [33-38]. Myeloid cell differentiation
arrest by miR-125b was also found in leukemia. M.
Bousquet et al. demonstrated that miR-125b was able to
interfere with primary human CD34+ cell differentiation
and overexpression of miR-125b is sufficient both to
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to independently induce leukemia in a mouse model
[39,40]. These results reveal that miR-125b is important
in cancer development.
The most important finding of this study was the dis-
covery that miR-125b levels are related to the treatment
response in pediatric APL patients. In patients with APL
and positive PML-RARa gene fusion, miR-125b
Figure 5 Apoptosis after knockdown of Bak1 and the involvement of miR-125b in drug-resistant leukemic cells. (A) Western blotting
images showing low Bak1 protein expression when NB4 cells were transfected with three different strands of si-RNA of Bak1. (B), (C) and (D) The
NB4 cells were transfected with 100 nM si-RNA control, a strand of si-Bak1-3 or a mixture of these three strands of si-Bak. Forty-eight hours
following transfection, camptothecin was added and cells were labeled with Annexin V/PI and analyzed by flow cytometry. Three independent
experiments were performed and similar results were obtained. (E) miR-125b expression was up-regulated in drug-resistant cell lines compared
to their drug-sensitive parental cells. *p < 0.05 compared with corresponding parents cells. (F) Transfection of HL60/DOX cells with miR-125b
duplex increases their resistance to DOX treatment. The IC50 of HL60/DOX cells transfected with miR-125b duplex was higher (p < 0.05)
compared with the IC50 for HL60/DOX cells transfected with miRNA duplex control and miR-195. Three independent experiments were
performed.
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subtypes of AML, suggesting that miR-125b may be
involved in PML/RARA-positive pediatric APL patients.
However, the detailed mechanism of its role remains to
be characterized. Notably, we found that miR-125b
expression is associated with both disease development
and treatment response. These results thus suggest a
potential that miR-125b m a yr e p r e s e n tas u i t a b l eb i o -
marker for predicting the effect of chemotherapy.
Shi et al. showed that in prostate cancer, upregulated
miR-125b could promote proliferation and targets Bak1
[40,41]. Zhou et al. demonstrated that Bak1 is a direct tar-
get of miR-125b in breast cancer [42]. However, the role
of miR-125b in leukemia, especially in pediatric APL,
remains unclear. We also found an inverse correlation
between levels of miR-125b and Bak1 and obtained strong
evidence that miR-125b could directly inhibit Bak1 expres-
sion in pediatric APL. Taken together, these findings sug-
gest that up-regulated miR-125b m a yb ep a r to fa
common regulatory pathway in different cancers. Further-
more, exogenous miR-125b is capable of promoting prolif-
eration of malignant cells. This finding indicates that miR-
125b may function as an oncogene by inhibiting APL cell
apoptosis and promoting APL cell proliferation.
Although conventional therapy, such as the modified
PETHEMALPA99 protocol, succeeded in obtaining long
term CR in more than 70% of APL patients, early death
and relapse in some patients are still a major concern in
therapeutics, especially for pediatric APL. However, the
mechanism of the patients’ resistance to chemothera-
peutic treatment is not entirely clear. Therefore, distin-
guishing the reason behind drug resistance and
developing biomarkers are critical.
We have shown that miR-125b differentially expressed
between pediatric APL primary, CR and relapse patients,
suggesting a potential that high miR-125b expression
m i g h tb eu s e da sab i o m a r k e r to indicate the treatment
response of pediatric APL patients, although the detailed
mechanism is still unknown. More importantly, trans-
fection of NB4 and HL60 cells with miR-125b effectively
inhibited apoptosis of these leukemic cells. Previously,
M. Bousquet et al. reported that miR-125b was able to
block the differentiation of NB4 cells induced by ATRA
[39]. Recently, miR-125b was also found associated with
drug resistance in breast cancer and pediatric acute lym-
phoblastic leukemia [42,43]. In this study, we also
demonstrated that up-regulation of miR-125b in pedia-
tric APL cells can increase their resistance to therapeu-
tic drugs. We speculated that increased miR-125b
expression might block the differentiation of hemato-
poietic precursors and respond to induction by ATRA
or other chemotherapeutic drugs.
The expression of miR-125b both in pediatric and adult
leukemia is currently not well understood. In adult APL,
M. Bousquet et al. showed that myelodysplastic syn-
drome and AML patients carrying the t(2;11)(p21;q23)
translocation were associated with miR-125b up-regula-
tion [39]; however, they only studied 19 adult leukemia
patients carrying the t(2;11)(p21;q23) translocation and
did not determine whether the expression of miR-125b
was up-regulated in adult APL patients. Another miRNA
expression profiling assay suggested that miR-125b was
up-regulated in seven adult APL patients, but this was
not validated [44]. Thus, miR-125b expression should be
further examined on a large scale with adult APL
patients. Remarkably, in our large-scale qRT-PCR assay
using 131 pediatric primary AML samples (M1 to M6),
we found that miR-125b was exceptionally highly
expressed in the pediatric APL subtype compared with
other AML subtypes. Because pediatric AML is a hetero-
geneous disease made up of various leukemia subtypes
that differ markedly in their cytogenetics, the identifica-
tion of these specific cytogenetic characteristics within
each subtype will be helpful for elucidating the mechan-
ism of oncogenesis in particular AML subtypes. Further-
more, this information may benefit the design of
chemotherapeutic strategies for patients.
I nc o n c l u s i o n ,t h i si st h ef i r s ts t u d yo fmiR-125b
expression in pediatric APL patients. Our results suggest
that miR-125b might be used as a biomarker of malig-
nancy and as a biomarker to evaluate the effectiveness
of chemotherapy in pediatric APL. We also found that
miR-125b promots proliferation and inhibits cell apopto-
sis at least partially mediated by targeting tumor sup-
pressor Bak1 in pediatric APL. More importantly,
forcing expression of miR-125b can increase resistance
to therapeutic drugs, suggesting that miR-125b is a
potential therapeutic target for pediatric APL failure.
Additional material
Additional file 1: Table S1. AML treatment protocol.
Additional file 2: Figure S1. The efficiencies of PCR amplification of
miR-125b and U6. The efficiencies of PCR amplification of both miR-
125b (A) and U6 (B) from the same patient are higher than 95%. A ten-
fold dilution of total RNA was used from 100 ng to 0.01 ng.
Additional file 3: Table S2. Primers information.
Additional file 4: Figure S2. Luciferase reporter assay analyzed the
targets of miR-125b and miR-125b expression level in HL60 cells
after transfection using the electroporation method. (A) Luciferase
activity was decreased because the 3’ UTR of BAK1, MAP3K, MCL1 and
TRIAP1 was binding to miR-125b. (B) miR-125b expression level in HL60
cells was measured by qRT-PCR analysis after transfection with miRNA
scrambled duplex, miR-125b mimics, miRNA inhibitor negative control
and miR-125b inhibitor. Error bars represent standard deviation and were
obtained from three independent experiments.
Additional file 5: Figure S3. miR-125b promotes cell proliferation in
NB4. (A) The qRT-PCR assay was used to measure expression profiles of
miR-125b. Data presented are the fold changes of miR-125b in NB4 cells
transduced with lv-miR-125b and lv-Src; (B) Cell proliferation was
detected using CCK-8 assay. NB4, NB4-miR-125b and NB4-Scr cells with
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Page 11 of 13different expression profiles of miR-125b were induced by 1 uM ATRA
and cell proliferation was measured at 24 hrs, 48 hrs and 72 hrs. *p <
0.05 compared with mock (NB4) and NB4-Scr.
Additional file 6: Figure S4. miR-125b inhibits apoptosis in HL60
cells and increases NB4-R1 cells resistance to ATRA treatment. (A)
The HL60 cells were transfected with 100 nM antisense control or miR-
125b antisense, respectively. Forty-four hours following transfection,
camptothecin was added to induce cells for four hours and then cells
were labeled with Annexin V/PI and analyzed by flow cytometry. Three
independent experiments were performed and similar results were
obtained. (B) Transfection of NB4-R1 cells with miR-125b duplex increases
their resistance to ATRA treatment. Three independent experiments were
performed.
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